Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

525 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Performance of ChatGPT-4 and Bard chatbots in responding to common patient questions on prostate cancer 177Lu-PSMA-617 therapy.
Belge Bilgin G, Bilgin C, Childs DS, Orme JJ, Burkett BJ, Packard AT, Johnson DR, Thorpe MP, Riaz IB, Halfdanarson TR, Johnson GB, Sartor O, Kendi AT. Belge Bilgin G, et al. Among authors: sartor o. Front Oncol. 2024 Jul 12;14:1386718. doi: 10.3389/fonc.2024.1386718. eCollection 2024. Front Oncol. 2024. PMID: 39070149 Free PMC article.
Theranostics and artificial intelligence: new frontiers in personalized medicine.
Belge Bilgin G, Bilgin C, Burkett BJ, Orme JJ, Childs DS, Thorpe MP, Halfdanarson TR, Johnson GB, Kendi AT, Sartor O. Belge Bilgin G, et al. Among authors: sartor o. Theranostics. 2024 Mar 25;14(6):2367-2378. doi: 10.7150/thno.94788. eCollection 2024. Theranostics. 2024. PMID: 38646652 Free PMC article. Review.
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R, Cheng HH, Schweizer MT, Sokolova AO, Agarwal N, Barata P, Sartor O, Bastos D, Smaletz O, Berchuck JE, McClure H, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Mehra N, Nelson PS, Hwang J, Dehm SM, Shi Q, Fleischmann Z, Sokol ES, Elliott A, Huang H, Bryce A, Marshall CH, Antonarakis ES. Orme JJ, et al. Among authors: sartor o. Eur Urol Oncol. 2024 Aug;7(4):877-887. doi: 10.1016/j.euo.2023.11.014. Epub 2023 Dec 9. Eur Urol Oncol. 2024. PMID: 38072760
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Joung JY, Sugimoto M, Sartor O, Liu YZ, Poehlein C, Barker L, Del Rosario PM, Armstrong AJ. Saad F, et al. Among authors: sartor o. Lancet Oncol. 2023 Oct;24(10):1094-1108. doi: 10.1016/S1470-2045(23)00382-0. Epub 2023 Sep 12. Lancet Oncol. 2023. PMID: 37714168 Clinical Trial.
Structurally-oriented classification of FOXA1 alterations identifies prostate cancers with opposing clinical outcomes and distinct molecular and immunologic subtypes.
Hwang J, Likasitwatanakul P, Deshmukh SK, Wu S, Kwon JJ, Toye E, Moline D, Evans MG, Elliott A, Passow R, Luo C, John E, Gandhi N, McKay RR, Heath EI, Nabhan C, Reizine N, Orme JJ, Domingo Domenech JM, Sartor O, Baca SC, Dehm SM, Antonarakis ES. Hwang J, et al. Among authors: sartor o. Clin Cancer Res. 2025 Jan 2. doi: 10.1158/1078-0432.CCR-24-3471. Online ahead of print. Clin Cancer Res. 2025. PMID: 39745364
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.
Shore N, Nielsen SM, Esplin ED, Antonarakis ES, Barata PC, Beer TM, Beltran H, Bryce A, Cookson MS, Crawford ED, Dorff TB, George DJ, Heath EI, Helfand BT, Hussain M, Mckay RR, Morgans AK, Morris MJ, Paller CJ, Ross AE, Sartor O, Shen J, Sieber P, Smith MR, Wise DR, Armstrong AJ. Shore N, et al. Among authors: sartor o. JCO Oncol Pract. 2024 Dec 19:OP2400626. doi: 10.1200/OP-24-00626. Online ahead of print. JCO Oncol Pract. 2024. PMID: 39700441
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024.
Bryce AH, Agarwal N, Beltran H, Hussain MH, Sartor O, Shore N, Antonarakis ES, Armstrong AJ, Calais J, Carducci MA, Dorff TB, Efstathiou JA, Gleave M, Gomella LG, Higano C, Hope TA, Iagaru A, Morgans AK, Morris DS, Morris MJ, Petrylak DP, Reiter RE, Rettig MB, Ryan CJ, Sellinger SB, Spratt DE, Srinivas S, Tagawa ST, Taplin ME, Yu EY, Zhang T, McKay RR, Koo PJ, Crawford ED. Bryce AH, et al. Among authors: sartor o. Cancer. 2025 Jan 1;131(1):e35612. doi: 10.1002/cncr.35612. Epub 2024 Dec 1. Cancer. 2025. PMID: 39616467 Free PMC article.
525 results